Indian Courts asked to revoke Ranbaxy's manufacturing license

India asked to pull Ranbaxy license over quality problems

The Indian Supreme Court has been asked to cancel Ranbaxy’s manufacturing license in the wake of quality problems that earned the firm a US import ban.

Late last week Indian media outlets (Business Standard, Live Mint) reported that the Court had notified the drugmaker of the request, which was submitted by activist lawyer Manohar Lal Sharma in a Public Interest Litigation (PIL) filing.

The reports suggest that Sharma has accused Ranbaxy of making sub-standard drugs – citing the current US import ban – and asked the courts to revoke the firm’s license and initiate an investigation of its activities.

According to The Hindu Chief Justice Sathasivam – who has been tasked with reviewing the PIL - decided not to order Ranbaxy to halt production immediately pending a full review of the firm’s operations.

The Supreme Court has yet to publish full details of the PIL and did not respond to’s request for confirmation.

In an emailed statement Ranbaxy told us it “has not yet received any notice to file reply from the Hon’ble Supreme Court of India. If the company receives a notice, it will respond appropriately to the observations.

Ranbaxy is compliant with all the requirements under Indian Law and maintains that all the drugs sold by the company in the Indian market are safe and effective.”


The PIL is not the first to be filed against Ranbaxy by Sharma. Last year he asked the Court to revoke the drugmaker’s manufacturing license citing its problems with the US Food and Drug Administration (FDA).

According to a report by the Business Standard the 2013 appeal was rejected by the Court, which said told Sharma his “entire argument is based on proceedings in the US. We have no jurisdiction over it.

Show us material that things are happening in India and it adversely affects right to life of people here.”

Related News

API sales down 81% as Ranbaxy feels fallout from US import alerts

API sales down 81% as Ranbaxy feels fallout from US import alerts

Sterility is one of the top issues cited by the German NCA

German regulators hit Ranbaxy with another warning letter

Sun and Ranbaxy merger will form India's largest pharma firm

Sun closes in on Ranbaxy deal with CCI approval

Will this be the first of many biosimilars to hit the Indian market?

Ranbaxy launches India’s first Remicade biosimilar

Image: iStock/VIPDesignUSA

Concealed compliance info lands ex-Ranbaxy owners $385m costs

Ranbaxy's January recall grabs hit the headlines last week

‘New’ Ranbaxy generic Lipitor recall took place in January

Ranbaxy voluntarily halts production at Toansa and Dewas API plants

Ranbaxy voluntarily halts production at its Indian API plants

Indian API plant receives US FDA 483

Ranbaxy receives US FDA Form 483 at Indian API plant

Another plant falls under US FDA's consent decree for Ranbaxy

Daiichi says new API import ban will affect Ranbaxy's US ops

Related Products

See more related products